Literature DB >> 26653833

ACR Appropriateness Criteria Acute Nonspecific Chest Pain-Low Probability of Coronary Artery Disease.

Udo Hoffmann1, Scott R Akers2, Richard K J Brown3, Kristopher W Cummings4, Ricardo C Cury5, S Bruce Greenberg6, Vincent B Ho7, Joe Y Hsu8, James K Min9, Kalpesh K Panchal10, Arthur E Stillman11, Pamela K Woodard4, Jill E Jacobs12.   

Abstract

Primary imaging options in patients at low risk for coronary artery disease (CAD) who present with undifferentiated chest pain and without signs of ischemia are functional testing with exercise or pharmacologic stress-based electrocardiography, echocardiography, or myocardial perfusion imaging to exclude myocardial ischemia after rule-out of myocardial infarction and early cardiac CT because of its high negative predictive value to exclude CAD. Although possible, is not conclusive whether triple-rule-out CT (CAD, pulmonary embolism, and aortic dissection) might improve the efficiency of patient management. More advanced noninvasive tests such as cardiac MRI and invasive imaging with transesophageal echocardiography or coronary angiography are rarely indicated. With increased likelihood of noncardiac causes, a number of diagnostic tests, among them ultrasound of the abdomen, MR angiography of the aorta with or without contrast, x-ray rib views, x-ray barium swallow, and upper gastrointestinal series, can also be appropriate. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. This recommendation is based on excellent evidence, including several randomized comparative effectiveness trials and blinded observational cohort studies.
Copyright © 2015 American College of Radiology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26653833     DOI: 10.1016/j.jacr.2015.09.004

Source DB:  PubMed          Journal:  J Am Coll Radiol        ISSN: 1546-1440            Impact factor:   5.532


  4 in total

1.  Clinical applications of cardiac computed tomography: a consensus paper of the European Association of Cardiovascular Imaging-part I.

Authors:  Gianluca Pontone; Alexia Rossi; Marco Guglielmo; Marc R Dweck; Oliver Gaemperli; Koen Nieman; Francesca Pugliese; Pal Maurovich-Horvat; Alessia Gimelli; Bernard Cosyns; Stephan Achenbach
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2022-02-22       Impact factor: 6.875

Review 2.  Non-invasive assessment of low- and intermediate-risk patients with chest pain.

Authors:  Pelbreton C Balfour; Jorge A Gonzalez; Christopher M Kramer
Journal:  Trends Cardiovasc Med       Date:  2016-09-12       Impact factor: 6.677

3.  Evaluation of computed tomography in patients with atypical angina or chest pain clinically referred for invasive coronary angiography: randomised controlled trial.

Authors:  Marc Dewey; Matthias Rief; Peter Martus; Benjamin Kendziora; Sarah Feger; Henryk Dreger; Sascha Priem; Fabian Knebel; Marko Böhm; Peter Schlattmann; Bernd Hamm; Eva Schönenberger; Michael Laule; Elke Zimmermann
Journal:  BMJ       Date:  2016-10-24

4.  Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia.

Authors:  Marc Dewey; Maria Siebes; Marc Kachelrieß; Klaus F Kofoed; Pál Maurovich-Horvat; Konstantin Nikolaou; Wenjia Bai; Andreas Kofler; Robert Manka; Sebastian Kozerke; Amedeo Chiribiri; Tobias Schaeffter; Florian Michallek; Frank Bengel; Stephan Nekolla; Paul Knaapen; Mark Lubberink; Roxy Senior; Meng-Xing Tang; Jan J Piek; Tim van de Hoef; Johannes Martens; Laura Schreiber
Journal:  Nat Rev Cardiol       Date:  2020-02-24       Impact factor: 32.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.